Is Dihexa legal in Pennsylvania?
status · caveats apply
Preclinical HGF/angiotensin IV mimetic; no human clinical trials registered; no FDA approval; sold widely as 'RUO' through nootropic vendors. No state-level peptide restrictions beyond federal law in Pennsylvania.
category: no approval · last verified May 13, 2026
§ 01
Quick answer
Preclinical HGF/angiotensin IV mimetic; no human clinical trials registered; no FDA approval; sold widely as 'RUO' through nootropic vendors. No state-level peptide restrictions beyond federal law in Pennsylvania.
§ 02
Full status breakdown
Federal status
FDA approval
no approval
DEA scheduling
not scheduled
503A compounding
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: Pre-IND compound. Any commercial human-use sale is an FDCA §505 violation. Sold widely as 'RUO' through nootropic vendors.
Personal possession: Not federally criminalized.
Pennsylvania — state-specific
Sport-body status
WADA 2026
not on prohibited list
Not explicitly named. Class-effect interpretation possible if HGF-mimetic captured under growth-factor language.
USADA
unknown
NCAA
unknown
What we couldn’t verify
§ 03
Also known as
Dihexa is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
PNB-0408N-hexanoic-Tyr-Ile-(6) amino hexanoic amideAngiotensin IV analogHGF mimetic
§ 04
Disclaimer
§ 05
Related
- Back to peptide legality lookup — pick a different compound or state
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
the roundup · monthly
Receipts in your inbox. Once a month.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
14,200 subscribers· 0 sponsored items· 11 issues since launch